Orthocell Ltd OCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.38
- Day Range
- A$0.39–0.40
- 52-Week Range
- A$0.32–0.46
- Bid/Ask
- A$0.39 / A$0.40
- Market Cap
- A$81.64 Mil
- Volume/Avg
- 215,464 / 128,678
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.69
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.orthocell.com.au
Comparables
Valuation
|
Metric
|
OCC
|
BLU
|
AUPH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 34.76 | 5.83 | 1.91 |
Price/Sales | 15.69 | — | 4.09 |
Price/Cash Flow | — | — | — |
Price/Earnings
OCC
BLU
AUPH
Financial Strength
|
Metric
|
OCC
|
BLU
|
AUPH
|
|---|---|---|---|
Quick Ratio | 4.35 | 32.13 | 4.85 |
Current Ratio | 4.60 | 33.42 | 5.50 |
Interest Coverage | — | −1,125.80 | −33.04 |
Quick Ratio
OCC
BLU
AUPH
Profitability
|
Metric
|
OCC
|
BLU
|
AUPH
|
|---|---|---|---|
Return on Assets (Normalized) | — | −21.75% | −7.67% |
Return on Equity (Normalized) | — | −26.24% | −10.09% |
Return on Invested Capital (Normalized) | — | −24.47% | −11.04% |
Return on Assets
OCC
BLU
AUPH
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ytsszvwgf | Fsmt | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pvrbylly | Vthrvgw | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rszbhkjt | Djmnvq | $98.3 Bil | |
MRNA
| Moderna Inc | Hxqklqnjf | Xhyhf | $42.7 Bil | |
ARGX
| argenx SE ADR | Gylyjdy | Xfrh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Sdkvpcxz | Xtg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Drhpssvh | Mhzkwgh | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lmwssfl | Zvtxjs | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Txlrjkzrmm | Hcfcsr | $12.7 Bil | |
INCY
| Incyte Corp | Ygffflfs | Zqdjwt | $11.8 Bil |